ArticleChinese journal of integrative medicine2026
Dendrobium officinale Polysaccharides Protected against CCl
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential anti-liver fibrosis (LF) effects of Dendrobium officinale polysaccharides (DOPs) and to further explore the involvement of the antioxidant and anti-inflammatory mechanisms of the transforming growth factor-beta 1 (TGF-β1) and Wnt signaling pathways.
methodsSeventy male Sprague-Dawley rats were assigned to 5 groups in a randomized block design: control, model, colchicine (COL, 0.1 mg/kg), low-dose DOP (LDD, 0.05 g/kg), and high-dose DOP (HDD, 0.1 g/kg) groups (n=14 per group). LF rat model was induced via subcutaneous injection of carbon tetrachloride (CCl
resultsCompared with the model group, HDD dramatically improved liver appearance and index, and alleviated extensive hepatocyte degeneration, interstitial fibrous proliferation, and pseudolobuli formation (P<0.01). Moreover, HDD downregulated mRNA and protein levels of α-smooth muscle actin, type I collagen, and type III collagen in the liver tissue of rats, while maintaining the MMP-1/TIMP-1 ratio by upregulating MMP-1 and downregulating TIMP-1 (P<0.05 or P<0.01). The ARFI and CEUS examination results also confirmed that HDD had significant anti-LF effects. HDD inhibited activation of the TGF-β and Wnt/β-catenin signaling pathways by reducing mRNA and protein levels of TGF-β1, Wnt-1 and β-catenin, while increasing the expression of dickkopf-1 (P<0.05 or P<0.01).
conclusionsDOPs achieved an anti-LF effect by inhibiting TGF-β1 and Wnt/β-catenin signaling. ARFI and CEUS can be used to evaluate the liver stiffness, microcirculation disorders, and drug efficacy in LF and cirrhosis.
Indexed as
Identifiers
41111081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.